These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 23185377)

  • 1. Dysferlin-peptides reallocate mutated dysferlin thereby restoring function.
    Schoewel V; Marg A; Kunz S; Overkamp T; Carrazedo RS; Zacharias U; Daniel PT; Spuler S
    PLoS One; 2012; 7(11):e49603. PubMed ID: 23185377
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dysferlin interacts with affixin (beta-parvin) at the sarcolemma.
    Matsuda C; Kameyama K; Tagawa K; Ogawa M; Suzuki A; Yamaji S; Okamoto H; Nishino I; Hayashi YK
    J Neuropathol Exp Neurol; 2005 Apr; 64(4):334-40. PubMed ID: 15835269
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dysferlin-deficient muscular dystrophy features amyloidosis.
    Spuler S; Carl M; Zabojszcza J; Straub V; Bushby K; Moore SA; Bähring S; Wenzel K; Vinkemeier U; Rocken C
    Ann Neurol; 2008 Mar; 63(3):323-8. PubMed ID: 18306167
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel sequence variants in dysferlin-deficient muscular dystrophy leading to mRNA decay and possible C2-domain misfolding.
    Wenzel K; Carl M; Perrot A; Zabojszcza J; Assadi M; Ebeling M; Geier C; Robinson PN; Kress W; Osterziel KJ; Spuler S
    Hum Mutat; 2006 Jun; 27(6):599-600. PubMed ID: 16705711
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proteasome inhibitors increase missense mutated dysferlin in patients with muscular dystrophy.
    Azakir BA; Erne B; Di Fulvio S; Stirnimann G; Sinnreich M
    Sci Transl Med; 2014 Aug; 6(250):250ra112. PubMed ID: 25143362
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutation impact on dysferlin inferred from database analysis and computer-based structural predictions.
    Therrien C; Dodig D; Karpati G; Sinnreich M
    J Neurol Sci; 2006 Dec; 250(1-2):71-8. PubMed ID: 16996541
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Calcium-sensitive phospholipid binding properties of normal and mutant ferlin C2 domains.
    Davis DB; Doherty KR; Delmonte AJ; McNally EM
    J Biol Chem; 2002 Jun; 277(25):22883-8. PubMed ID: 11959863
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pathogenic mutation R959W alters recognition dynamics of dysferlin inner DysF domain.
    Espinoza-Fonseca LM
    Mol Biosyst; 2016 Mar; 12(3):973-81. PubMed ID: 26806107
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identical mutation in patients with limb girdle muscular dystrophy type 2B or Miyoshi myopathy suggests a role for modifier gene(s).
    Weiler T; Bashir R; Anderson LV; Davison K; Moss JA; Britton S; Nylen E; Keers S; Vafiadaki E; Greenberg CR; Bushby CR; Wrogemann K
    Hum Mol Genet; 1999 May; 8(5):871-7. PubMed ID: 10196377
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The C2 domains of dysferlin: roles in membrane localization, Ca
    Muriel J; Lukyanenko V; Kwiatkowski T; Bhattacharya S; Garman D; Weisleder N; Bloch RJ
    J Physiol; 2022 Apr; 600(8):1953-1968. PubMed ID: 35156706
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proteasomal inhibition restores biological function of mis-sense mutated dysferlin in patient-derived muscle cells.
    Azakir BA; Di Fulvio S; Kinter J; Sinnreich M
    J Biol Chem; 2012 Mar; 287(13):10344-10354. PubMed ID: 22318734
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment with Recombinant Human MG53 Protein Increases Membrane Integrity in a Mouse Model of Limb Girdle Muscular Dystrophy 2B.
    Gushchina LV; Bhattacharya S; McElhanon KE; Choi JH; Manring H; Beck EX; Alloush J; Weisleder N
    Mol Ther; 2017 Oct; 25(10):2360-2371. PubMed ID: 28750735
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modular dispensability of dysferlin C2 domains reveals rational design for mini-dysferlin molecules.
    Azakir BA; Di Fulvio S; Salomon S; Brockhoff M; Therrien C; Sinnreich M
    J Biol Chem; 2012 Aug; 287(33):27629-36. PubMed ID: 22736764
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Translational research and therapeutic perspectives in dysferlinopathies.
    Barthélémy F; Wein N; Krahn M; Lévy N; Bartoli M
    Mol Med; 2011; 17(9-10):875-82. PubMed ID: 21556485
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The absence of dysferlin induces the expression of functional connexin-based hemichannels in human myotubes.
    Cea LA; Bevilacqua JA; Arriagada C; Cárdenas AM; Bigot A; Mouly V; Sáez JC; Caviedes P
    BMC Cell Biol; 2016 May; 17 Suppl 1(Suppl 1):15. PubMed ID: 27229680
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic exon skipping for dysferlinopathies?
    Aartsma-Rus A; Singh KH; Fokkema IF; Ginjaar IB; van Ommen GJ; den Dunnen JT; van der Maarel SM
    Eur J Hum Genet; 2010 Aug; 18(8):889-94. PubMed ID: 20145676
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Amyloidosis in muscular dystrophy].
    Carl M; Röcken C; Spuler S
    Pathologe; 2009 May; 30(3):235-9. PubMed ID: 19326120
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Crystal structures of the human Dysferlin inner DysF domain.
    Sula A; Cole AR; Yeats C; Orengo C; Keep NH
    BMC Struct Biol; 2014 Jan; 14():3. PubMed ID: 24438169
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dysferlin interacts with calsequestrin-1, myomesin-2 and dynein in human skeletal muscle.
    Flix B; de la Torre C; Castillo J; Casal C; Illa I; Gallardo E
    Int J Biochem Cell Biol; 2013 Aug; 45(8):1927-38. PubMed ID: 23792176
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dysferlin deficiency enhances monocyte phagocytosis: a model for the inflammatory onset of limb-girdle muscular dystrophy 2B.
    Nagaraju K; Rawat R; Veszelovszky E; Thapliyal R; Kesari A; Sparks S; Raben N; Plotz P; Hoffman EP
    Am J Pathol; 2008 Mar; 172(3):774-85. PubMed ID: 18276788
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.